ALPMF - Apellis falls on potential EU snub for eye therapy
2023-12-14 07:47:47 ET
More on Apellis Pharma
- Apellis Pharmaceuticals: Focus Shifts Toward Market Share After Apparent Safety Resolution
- Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript
- Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Apellis adds safety warning to eye therapy
- Apellis Pharmaceuticals reports insider transactions worth $1.9M
For further details see:
Apellis falls on potential EU snub for eye therapy